PureTech rejects cash exit proposal from Nordic Capital, investment firm says it won't make an offer

Kyle LaHucik

Senior Reporter

PureTech Health, a Boston biopharma company that has created drug developers like Karuna Therapeutics and Seaport Therapeutics, confirmed on Monday that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

PureTech rejects cash exit proposal from Nordic Capital, investment firm says it won't make an offer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‘This is self-inflicted’: Leerink’s David Risinger on the market shock and hits to biopharma

Stock market melts down over Trump’s tariffs, and biotech's pain keeps growing

RFK Jr. won’t testify before key Senate committee this week on HHS overhaul

Rare disease hub at CDER and CBER faces new reality with staff crunch

HHS says it may revisit anti-obesity drug policies after dropping Biden-era proposal

Drug tool and packaging makers to feel brunt of Trump tariffs, analysts say

PureTech re­jects cash ex­it pro­pos­al from Nordic Cap­i­tal, in­vest­ment firm says it won't make an of­fer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

‘This is self-in­flict­ed’: Leerink’s David Risinger on the mar­ket shock and hits to bio­phar­ma

Stock mar­ket melts down over Trump’s tar­iffs, and biotech's pain keeps grow­ing

RFK Jr. won’t tes­ti­fy be­fore key Sen­ate com­mit­tee this week on HHS over­haul

Rare dis­ease hub at CDER and CBER faces new re­al­i­ty with staff crunch

HHS says it may re­vis­it an­ti-obe­si­ty drug poli­cies af­ter drop­ping Biden-era pro­pos­al

Drug tool and pack­ag­ing mak­ers to feel brunt of Trump tar­iffs, an­a­lysts say

PureTech rejects cash exit proposal from Nordic Capital, investment firm says it won't make an offer

‘This is self-inflicted’: Leerink’s David Risinger on the market shock and hits to biopharma

Stock market melts down over Trump’s tariffs, and biotech's pain keeps growing

RFK Jr. won’t testify before key Senate committee this week on HHS overhaul

Rare disease hub at CDER and CBER faces new reality with staff crunch

HHS says it may revisit anti-obesity drug policies after dropping Biden-era proposal

Drug tool and packaging makers to feel brunt of Trump tariffs, analysts say